These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 22231340)
1. Suicide without depression after withdrawal of a dopamine agonist in a patient with Parkinson's disease. Flament M; Loas G; Godefroy O; Krystkowiak P J Neuropsychiatry Clin Neurosci; 2011; 23(4):E32. PubMed ID: 22231340 [No Abstract] [Full Text] [Related]
5. Suicide attempt in a dopamine agonist withdrawal syndrome in Parkinson's disease. Espindola M; Rojas NG; Vaisentein G; Da Prat G; Cesarini M; Etcheverry JL; Gatto EM Parkinsonism Relat Disord; 2024 Apr; 121():106017. PubMed ID: 38401377 [TBL] [Abstract][Full Text] [Related]
6. Identification of possible risk factors for the development of dopamine agonist withdrawal syndrome in Parkinson's disease. Cunnington AL; White L; Hood K Parkinsonism Relat Disord; 2012 Nov; 18(9):1051-2. PubMed ID: 22677468 [No Abstract] [Full Text] [Related]
11. A Man With Persistent Dopamine Agonist Withdrawal Syndrome After 7 Years Being Off Dopamine Agonists. Huynh NT; Sid-Otmane L; Panisset M; Huot P Can J Neurol Sci; 2016 Nov; 43(6):859-860. PubMed ID: 26842385 [No Abstract] [Full Text] [Related]
12. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion. Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817 [TBL] [Abstract][Full Text] [Related]
17. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Joutsa J; Martikainen K; Vahlberg T; Kaasinen V Parkinsonism Relat Disord; 2012 Dec; 18(10):1079-83. PubMed ID: 22784693 [TBL] [Abstract][Full Text] [Related]
18. Cancer risks among the users of ergot-derived dopamine agonists for Parkinson's disease, a nationwide population-based survey. Wang V; Chao TH; Hsieh CC; Lin CC; Kao CH Parkinsonism Relat Disord; 2015 Jan; 21(1):18-22. PubMed ID: 25457814 [TBL] [Abstract][Full Text] [Related]
19. Dopamine agonist switching in Parkinson's disease. Stewart D; Morgan E; Burn D; Grosset D; Chaudhuri KR; MacMahon D; Needleman F; Macphee G; Heywood P Hosp Med; 2004 Apr; 65(4):215-9. PubMed ID: 15127675 [TBL] [Abstract][Full Text] [Related]
20. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease. Ceravolo R; Rossi C; Del Prete E; Bonuccelli U Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]